Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 28-day, Single-armed, Open-label Trial to Evaluate Safety of the House Dust Mite (HDM) Sublingual Allergy Immunotherapy (SLIT) Tablet in Adolescent Subjects With HDM Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma

NCT04541004 is registered in ClinicalTrials.gov with ALK-Abelló A/S as lead sponsor.

NCT NCT04541004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04541004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 28-day, Single-armed, Open-label Trial to Evaluate Safety of the House Dust Mite (HDM) Sublingual Allergy Immunotherapy (SLIT) Tablet in Adolescent Subjects With HDM Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma
Lead sponsor
ALK-Abelló A/S
Phase
Phase 3
Overall status
Completed
Start date
September 23, 2020
Completion date
April 24, 2021
Enrollment
253 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

allergic rhinitis, allergic rhinoconjunctivitis